Status:
COMPLETED
Effects of Faecal Microbiota Transplantation in Patients With IBS
Lead Sponsor:
Helse Fonna
Collaborating Sponsors:
Helse Vest
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Irritable bowel syndrom (IBS) is a common chronic gastrointestinal disorder that affects 10-20% of the world population. The prevalence of IBS in Norway is between 8% and 25%. The pathophysiology of I...
Detailed Description
Study design Patients One hundred and seventy patients who fulfill the following inclusion criteria and lack the exclusion criteria shall be included. In addition, the patients are examined physically...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients between who fulfill Rome IV criteria for the diagnosis of IBS.
- Patients with moderate to severe IBS symptoms (IBS-SSS ≥ 175).
- Exclusion criteria:
- Pregnant, planning pregnancy or lactating women.
- The use of antibiotics or probiotics within 1 month prior to FMT.
- Patients who had undergone any abdominal surgery, with the exception of appendectomy, cholecystectomy, Caesarean section or hysterectomy.
Exclusion
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 5 2019
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT03822299
Start Date
January 1 2018
End Date
May 5 2019
Last Update
May 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helse Fonna
Haugesund, Norway, 5504